In an alternate approach, the addition of sunitinib (multi-tyrosine kinase inhibitor) to HUVEC endothelial cells has been recently shown to specifically prevent upregulation of Endocan, demonstrating another means to inhibit Endocan-tumor interactions. This evidence concerns the gene ESM1 and neoplasm.